The Chronic Unpredictable Mild Stress (CUMS) model is one of the most extensively characterized and clinically relevant rodent models for depression research. Repeated exposure to a series of mild and unpredictable stressors induces progressive behavioral abnormalities that resemble key symptoms observed in patients with major depressive disorder, including anhedonia, reduced motivation, and emotional dysfunction.

PharmaLegacy has established a robust and reproducible CUMS platform with standardized stress paradigms and longitudinal behavioral monitoring. Depression-like phenotypes are routinely assessed using the Sucrose Preference Test (SPT), enabling quantitative evaluation of anhedonia and disease progression throughout the study period. The model consistently produces stable behavioral deficits and provides a reliable platform for efficacy assessment.

The CUMS model serves as a valuable tool for investigating the neurobiological mechanisms underlying chronic stress and depression. It supports evaluation of small molecules, biologics, antibodies, oligonucleotide therapeutics, and other emerging CNS treatment modalities.

In addition to behavioral assessments, the platform can be integrated with histopathology, immunohistochemistry, molecular biomarker analysis, transcriptomics, and neural circuit studies to investigate disease mechanisms, target engagement, and therapeutic responses. This model is widely applicable for preclinical development programs focused on depression, stress-related disorders, and novel neuropsychiatric therapeutics.

The predictive validity of the PharmaLegacy CUMS platform has been demonstrated using clinically established antidepressants, including fluoxetine and venlafaxine. Chronic treatment significantly improves sucrose preference and reverses stress-induced behavioral deficits, supporting the translational relevance of the model for antidepressant drug discovery.

To provide a comprehensive assessment of therapeutic efficacy, multiple behavioral endpoints can be incorporated, including the Sucrose Preference Test (SPT) for evaluation of anhedonia and the Forced Swim Test (FST) for assessment of behavioral despair. These complementary measures enable robust characterization of antidepressant responses and treatment outcomes.

The model exhibits robust responsiveness to clinically established antidepressants and provides a reliable platform for assessing therapeutic efficacy across different treatment modalities. It is particularly useful for evaluating compounds targeting anhedonia, stress-related behavioral deficits, and mood-related dysfunctions associated with chronic stress exposure. Combined with molecular, cellular, and systems-level analyses, the CUMS platform provides a comprehensive framework for investigating antidepressant efficacy and the biological mechanisms underlying stress-induced mood disorders.